CTRI/2016/10/007348
Completed
未知
Evaluation of Efficacy, Safety and Tolerability of aCombination Therapy with Chlorzoxazone and Ibuprofencompared to Ibuprofen alone in the SymptomaticTreatment of Acute Low Back Pain (LBP): An Open-label,Prospective, Multi-center, Observational Study
Dr Reddys Laboratories Pvt Ltd0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dr Reddys Laboratories Pvt Ltd
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patient of either sex between 18 to 60 years of age
- •2\. Symptomatic with acute low back pain, with or without
- •radiating pain no lower than the knee, for less than 3 days
- •3\. Patients willing to take the medications as directed and
- •willing to come for the follow\-ups
- •4\. Willing to comply with the protocol requirements
- •5\. Willing to give the written informed consent
Exclusion Criteria
- •1\. Patients associated with other lumbar or cervical spinal
- •tract conditions such as spondylitis, fracture, cancers, severe
- •arthritis and osteoporosis.
- •2\. Muscular diseases such as myositis, poliomyositis, muscular
- •dystrophy and myotonia.
- •3\. Other known systemic diseases affecting the neurological or
- •endocrine system.
- •4\. Patients with moderate to severe hepatic impairment
- •(defined as increase in serum bilirubin, SGOT \& SGPT by
- •\>2\.5 times the upper reference level of the laboratory
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisEUCTR2019-002341-38-BEGM Biopharmaceuticals, Inc.150
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-002341-38-GBGM Biopharmaceuticals, Inc.150
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-002341-38-DEGM Biopharmaceuticals, Inc.150
Completed
Phase 4
A Clinical trial to study the effects and tolerability of Dacne gel containing Clindamycin Phosphate 1% and zinc acetate in patients suffering from acne.CTRI/2011/091/000041Glenmark Pharmaceuticals Ltd125